GlassScriptPhysician profile
Emily B Staggs
NPI 1023498938
$3,852.36
in general payments reported to CMS, 2019-2025
26 companies · $950 in 2025
The $950 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $176 · 2021: $242 · 2022: $309 · 2023: $869 · 2024: $1,117 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,937.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $806.53 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $617.23 | 2021-2025 | Ubrelvy, Qulipta, Dalvance |
| Pfizer INC. | $393.60 | 2023-2025 | |
| Novo Nordisk INC | $392.68 | 2019-2025 | Ozempic, Rybelsus |
| Inari Medical, INC. | $389.81 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.24 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $137.57 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $127.68 | 2019-2023 | |
| Amgen INC. | $123.91 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $106.66 | 2021-2025 | Jardiance, Mounjaro |
| Verona Pharma, INC. | $89.79 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $84.08 | 2020 | |
| Dexcom, INC. | $57.19 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $56.04 | 2023-2025 | |
| Stryker Corporation | $40.91 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.76 | 2021-2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $39.40 | 2025 | Voquezna |
| Astellas Pharma US INC | $38.81 | 2024 | Veozah |
| Genentech USA, INC. | $34.67 | 2019-2021 | |
| Medtronic, INC. | $28.76 | 2023 | Intellis Adaptivestim |
| Kowa Pharmaceuticals America, INC. | $24.65 | 2021 | |
| Abbott Laboratories | $20.33 | 2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $14.92 | 2022 | |
| Optinose US, INC. | $14.65 | 2021 | |
| Dynavax Technologies Corporation | $14.42 | 2023 | Heplisav-B |
| Esperion Therapeutics, INC. | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Staggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.